Lv5
1020 积分 2021-04-11 加入
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
18天前
已完结
Review: The quality of dying and death: a systematic review of measures
1个月前
已完结
The Quality of Dying and Death
1个月前
已完结
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
1个月前
已完结
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial
1个月前
已完结
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma
4个月前
已完结
The prognostic role of WeChat-based instant doctor–patient communication in patients with advanced pancreatic cancer
4个月前
已完结
Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study
4个月前
已完结
Understanding the global cancer statistics 2022: growing cancer burden
6个月前
已完结
皖公网安备34019202002308
